34.41 USD
▲-0.02+4.69%
2026-08-03
市值
$685.68M
市盈率
—
EPS
-4.55
股息率
—
52 周区间
15.93 – 43.66
成交量
142.21K
Beta
1.92
目标价
81.71
52W 低 15.9352W 高 43.66
价格走势
公司简介
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp...